Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7576302 | 1.00 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL8081055 | 1.00 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL2454978 | 0.92 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL3853492 | 0.92 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL10316997 | 0.92 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL2447834 | 0.92 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL5378432 | 0.92 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL1863581 | 0.88 | — | — | |
| SCHEMBL10346067 | 0.82 | — | — | |
| SCHEMBL7577177 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113025345-B | Liquid crystal composition containing polymerizable compound and liquid crystal display element | DIC株式会社 | 2024-02-09 | — | — | CN | disclosed |
| US-9717963-B2 | Golf club shaft | DUNLOP SPORTS CO. LTD. (JP) | 2017-08-01 | — | — | US | disclosed |
| US-20160367872-A1 | GOLF CLUB SHAFT | DUNLOP SPORTS CO. LTD. (JP) | 2016-12-22 | — | — | US | disclosed |
| US-20070083021-A1 | Fluorocopolymer, method for its production and resist composition containing it | ASAHI GLASS COMPANY, LIMITED (JP) | 2007-04-12 | — | — | US | disclosed |
| EP-1080104-B1 | CERTAIN HETEROARYL SUBSTITUTED THIOL INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | NOVARTIS AG (CH) | 2005-02-09 | — | — | EP | disclosed |
| EP-1440103-A1 | HARDENABLE MIXTURE OF SUBSTANCES, PRODUCTION METHOD AND USE THEREOF | BASF Coatings AG (DE) | 2004-07-28 | — | — | EP | disclosed |
| US-6689801-B2 | CARDIOVASCULAR DISORDERS; ANTIISCHEMIC AGENTS; HYPOTENSIVE AGENTS; GASTROINTESTINAL DISORDERS | NOVARTIS AG (CH) | 2004-02-10 | — | — | US | disclosed |
| US-6613782-B2 | For treating and/or preventing endothelin dependent conditions, e.g. cardio- and cerebro-vascular disorders such as hypertension, vasoconstriction, congestive heart failure, cerebral disorders, respiratory system disorders | NOVARTIS AG (CH) | 2003-09-02 | — | — | US | disclosed |
| WO-2003037952-A1 | HARDENABLE MIXTURE OF SUBSTANCES, PRODUCTION METHOD AND USE THEREOF | BASF COATINGS AG (DE) | 2003-05-08 | — | — | WO | disclosed |
| US-20030018057-A1 | Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme | FINK CYNTHIA ANNE (US) | 2003-01-23 | — | — | US | disclosed |
| WO-1999055723-A1 | CERTAIN HETEROARYL SUBSTITUTED THIOL INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | NOVARTIS AG (CH) | 1999-11-04 | — | — | WO | disclosed |
| US-5668158-A | TREATMENT OF CARDIOVASCULAR DISORDERS | NOVARTIS CORPORATION (US) | 1997-09-16 | — | — | US | disclosed |
| EP-0448726-B1 | 2-SUBSTITUTED 2-CYCLOPENTENONE AND CARCINOSTATIC AGENT AND OSTEOGENESIS PROMOTER CONTAINING THE SAME AS ACTIVE INGREDIENT | TEIJIN LTD (JP) | 1996-04-24 | — | — | EP | disclosed |
| US-5506244-A | TREATING CARDIOVASCULAR DISORDERS | CIBA-GEIGY CORPORATION (US) | 1996-04-09 | — | — | US | disclosed |
| US-5432186-A | Enzyme inhibitors | CIBA-GEIGY CORPORATION (US) | 1995-07-11 | — | — | US | disclosed |
| EP-0655461-A1 | Cyclic amino acid derivatives having ACE and NEP inhibiting activity | CIBA-GEIGY AG (CH) | 1995-05-31 | — | — | EP | disclosed |
| US-5338844-A | 2-substituted-2-cyclopentenone compound and anticancer agent and bone formation accelerator comprising same as active ingredient | TEIJIN LIMITED (JP) | 1994-08-16 | — | — | US | disclosed |
| US-5216183-A | Antitumor, anticarcinogenic agents; bone formation accelerators | TEIJIN LIMITED (JP) | 1993-06-01 | — | — | US | disclosed |
| EP-0448726-A1 | 2-SUBSTITUTED 2-CYCLOPENTENONE AND CARCINOSTATIC AGENT AND OSTEOGENESIS PROMOTER CONTAINING THE SAME AS ACTIVE INGREDIENT | TEIJIN LIMITED (JP) | 1991-10-02 | — | — | EP | disclosed |
| US-4933244-A | Phenolic epoxy polymer or polyester and charge transporting small molecule at interface between a charge generator layer and a charge transport layer | XEROX CORPORATION (US) | 1990-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018057-A1 | Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme | ECE1, ECE2, EDNRB | ALDH1A1 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.